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HIGHLIGHTS 
 There is a growing debate on the role of Aβ in the pathogenesis of AD. 
 A "one-fits-all" approach (based on a single biomarker/process) is inadequate for AD. 
 There is the need to overcome the traditional paradigms of "standalone-diseases". 
 A multidimensional modeling of biomarkers may have important implications. 
 
 Abstract 
 In these last years, several phase III randomized controlled trials testing promising 
candidates sharing Aβ depots as target of their action have failed, despite showing some 
reductions of the brain Aβ charge. The announcements of the negative results have heated the 
discussion in the field and divided the scientific community between the defenders versus the 
opponents of the Aβ theory. In the present article, we discuss the limits of these drastic, opposite 
positions and we propose a novel approach to Alzheimer’s disease (AD). In particular, a "one-fits-
all" approach where a single biomarker/process is able to explain the clinical manifestation seems 
inadequate for AD (as for other conditions of old age). Accordingly, there is an urgent need to 
overcome the traditional paradigms of "standalone-diseases" (requiring unimodal interventions) 
in favor of more comprehensive and multidimensional approaches. Specifically, promoting 
biomarker modeling procedures based on multivariate statistical methodologies may have 
important implications and advantages in the field of AD and other neurodegenerative diseases.  
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 Several phase III randomized controlled trials testing promising candidates sharing Aβ 
depots as target of their action have recently failed, despite showing some reductions of the brain 
Aβ charge[1]. The announcements of the negative results have heated the discussion in the field 
and divided the scientific community between the defenders versus the opponents of the amyloid 
theory. On one side, remaining convinced of the pivotal/causal role of Aβ in the pathogenesis of 
AD[2,3], some researchers have  attributed the failure of trials (considered only as “temporary 
setbacks”[2]) to the characteristics of the sample populations, the dosing of the compounds, 
and/or molecular specificities of the targets/mechanisms. They still firmly support the design and 
conduction of further research on anti-Aβ treatments, usually proposing the anticipation of 
interventions to milder/prodromal stages of the disease. On the other hand, there is a growing 
feeling that both research and industry have been over-reliant on Aβ to both define AD and 
develop treatments against it. For some critics, the disappointing findings coming from the recent 
trials inevitably confirm the non-centrality of Aβ in the pathophysiological processes leading to 
AD[4]. Consistently, they solicit at redirecting attention towards other mechanisms and pathways 
(e.g., tau, neuroinflammation, cell cycle and oxidative stress), despite the scarcity of defined and 
validated targets.  
 In our opinion, both reactions are understandable but rather drastic. Taken separately, 
they do not adequately interpret the results of the negative trials, potentially affecting future 
research in the field. It is not a matter to choosing whether embracing or rejecting the amyloid 
cascade hypothesis. Also thanks to these studies, we do know now that AD is an extremely 
complex condition, much more perhaps than what we thought. As all the age-related diseases, it is 
determined by multiple, simultaneous, and interacting pathophysiological processes, which make 
difficult to reduce everything to a single hypothesis or model. Based on recent evidence, it is 
increasingly being considered as a nosological "umbrella" covering multiple and heterogeneous 
conditions. This relevant complexity characterizes also the presenile variants, whose 
pathophysiology and phenotypic manifestations are not fully explained by an individual 
pathological process (i.e., Aβ deposition), even if predominant. Accordingly, a "one-fits-all" 
approach where a single biomarker/process is able to explain the clinical manifestation seems 
simply inadequate for AD (as for other conditions of old age). Under this perspective, models 
simultaneously considering multiple biomarkers for understanding the intricate biological 
background of age-related conditions have already been proposed[5]. The adoption of 
multivariate statistical methodologies may support a fundamental shift to a multidimensional 
modeling of complementary biomarkers. These methods may consent to properly capture the 
heterogeneity of neurodegeneration and the underlying pathophysiology by merging the 
information obtained from different sources of variability (e.g., circulating biomolecules, clinical 
parameters, imaging findings, genetic traits)[5]. In this regard, principal component analysis 
(PCA), analysis of variance (ANOVA) - simultaneous component analysis (ASCA), multilevel 
simultaneous component analysis (MSCA), and partial least squares - discriminant analysis (PLS-
DA), are few example of statistical approaches that are increasingly considered for exploring 
biomarkers for age-related conditions[5,6].  
 In conclusion, there is an urgent need to overcome the traditional paradigms of 
"standalone-diseases" (requiring unimodal interventions) in favor of more comprehensive and 
multidimensional approaches. The adoption of such novel methodology (valid for both the clinical 
and research settings) may lead to 1) a wiser consideration of past negative experiences for better 
informing future activities, 2) the development of person-tailored and function-driven 
interventions, and 3) avoid sterile barricades and divisions in the scientific community. Aβ remains 
a cornerstone of AD pathology. However, it should not be overcharged of responsibility but 
considered as only a piece of the complex puzzle of AD. Solving the whole picture only looking at it 
might simply be unrealistic. 
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